Bio-Path Holdings News: Why BPTH Stock Is Skyrocketing Today

Bio-Path Holdings news about the company not offering additional shares of its stock has BPTH up on Monday.

Biotech News: Why Advaxis Stock Is Soaring Today

Source: Shutterstock

Bio-Path Holdings (NASDAQ:) was planning to sell an additional 712,910 shares of BPTH stock to investors. It was pricing these shares at $25.95. However, the company’s stock has been trading below that price recently. It closed on Friday at $15.65.

If this new bit of Bio-Path Holdings news hadn’t come about, the company would have been increasing its outstanding share amount by 28%. The company’s total amount of outstanding shares was last recorded at 2.51 million as of March, 15, 2019, reports .

It’s possible that the withdrawal of the BPTH stock offering is an attempt to increase the price of its shares. The goal may be to get shares of BPTH up above the offer price of $25.95 before moving forward again with plans to increase its outstanding shares, notes.

BPTH stock was up 39% as of Monday morning and is up 311% since the start of the year. However, it’s worth noting that Bio-Path Holdings saw a reverse stock split of 1 for 20 in late January.

The stock also reached a peak of $73.52 on March 7 following positive data from a clinical trial. Despite this, it quickly fell back down to lower levels in the next couple of days. Even with this decline, it is was still sitting above its price prior to the data from the clinical trial.

As of this writing, William White did not hold a position in any of the aforementioned securities.

The post appeared first on InvestorPlace.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos


    InvestorPlace is one of America’s largest, longest-standing independent financial research firms. Started over 40 years ago by a business visionary named Tom Phillips, we publish detailed research and recommendations for self-directed investors, financial advisors and money managers.

    Learn More